Ewers S B, Attewell R, Baldetorp B, Borg A, Långström E, Killander D
Department of Oncology, University Hospital, Lund, Sweden.
Breast Cancer Res Treat. 1992 Jan;20(2):93-108. doi: 10.1007/BF01834639.
In a prospective study of a consecutive breast cancer series accumulated in the period 1978-82, the S-phase fraction (SPF) and ploidy status were determined by flow cytometry performed on cell nuclei derived from samples of 580 primary tumors. Sixty percent of the tumors were non-diploid. After correction for debris the median SPF values were 7.3% overall, 12% for non-diploid tumors, and 2.9% for diploid tumors (2.6% when nodal subsets N2 and N3 and cases with metastases at presentation were excluded). The SPF values correlated both to tumor size (p = 0.008) and to the number of positive axillary lymph nodes (p = 0.03). At clinical follow-up in 1986, 467 unilateral breast cancer patients who had undergone radical treatment for cure could be evaluated with respect to the prognostic value of both the SPF value and ploidy status. The median duration of follow-up was then 59 months (range 2-90), and the median time-to-recurrence 24 months (range 2-69, n = 137). At follow-up in 1991, 201/467 of the patients had died, the median duration of follow-up being 50 months (range 2-126) for the decreased, and 119 (range 6-148) for the survivors. In multivariate analysis (Cox's proportional hazards models), the strongest independent predictors of distant recurrence-free survival (DRFS) were the number of positive axillary lymph nodes (p less than 0.0001), the debris-corrected SPF value alone (p = 0.003, versus p = 0.05 for uncorrected value), and ploidy status combined with the corrected SPF value (p = 0.0002). When age was taken into account, both the corrected SPF value and the ploidy-SPF combination were predictors of crude survival (p = 0.006 and p = 0.002, respectively). In univariate life-table analysis, the 5-year DRFS rate was 93% in node-negative (N0) cases with an SPF less than 7.3%, as compared to 80% in those with an SPF greater than or equal to 7.3% (p = 0.005). Among node-positive cases, the prognostic value of the SPF was confined to those with 1-3 positive nodes, the 5-year DRFS rate being 68% in cases with an SPF less than 7.3%, as compared to 40% in cases with an SPF greater than or equal to 7.3% (p = 0.01).(ABSTRACT TRUNCATED AT 400 WORDS)
在一项对1978 - 1982年间积累的连续性乳腺癌系列病例的前瞻性研究中,通过对580例原发性肿瘤样本的细胞核进行流式细胞术检测,确定了S期细胞分数(SPF)和倍体状态。60%的肿瘤为非二倍体。校正碎片后,总体中位SPF值为7.3%,非二倍体肿瘤为12%,二倍体肿瘤为2.9%(排除N2和N3淋巴结亚组及初诊时有转移的病例后为2.6%)。SPF值与肿瘤大小(p = 0.008)和腋窝阳性淋巴结数量(p = 0.03)均相关。在1986年的临床随访中,对467例接受根治性治疗的单侧乳腺癌患者,就SPF值和倍体状态的预后价值进行了评估。当时的中位随访时间为59个月(范围2 - 90个月),中位复发时间为24个月(范围2 - 69个月,n = 137)。在1991年的随访中,467例患者中有201例死亡,死亡患者的中位随访时间为50个月(范围2 - 百26个月),存活患者为119个月(范围6 - 148个月)。在多变量分析(Cox比例风险模型)中,远处无复发生存(DRFS)的最强独立预测因素是腋窝阳性淋巴结数量(p < 0.0001)、单独的校正碎片后的SPF值(p = 0.003,未校正值为p = 0.05)以及倍体状态与校正后的SPF值相结合(p = 0.0002)。考虑年龄因素时,校正后的SPF值和倍体 - SPF组合均为总生存的预测因素(分别为p = 0.006和p = 0.002)。在单变量生命表分析中,SPF小于7.3%的淋巴结阴性(N0)病例的5年DRFS率为93%,而SPF大于或等于7.3%的病例为80%(p = 0.005)。在淋巴结阳性病例中,SPF的预后价值仅限于有1 - 3个阳性淋巴结的患者,SPF小于7.3%的病例的5年DRFS率为68%,而SPF大于或等于7.3%的病例为40%(p = 0.0